The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: A review

Current Opinion in Ophthalmology

Volumn 18, Issue 2, 2007, Pages 134-139

  Yee, Richard W ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Alpha agonist; Benzalkonium chloride; Beta blocker; Carbonic anhydrase inhibitor; Glaucoma; Preservative; Prostaglandin analogue (PGA)

Indexed keywords

ADRENALIN; ADRENALIN BORATE; ALPHAGAN P; APRACLONIDINE; BENZALKONIUM CHLORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BETOPTIC S; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBACHOL; CARBASTAT; CARTELOL; CARTEOLOL; COMBIGAN; DEMECARIUM; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; ECOTHIOPATE; ESERINE SULPHATE; GANFORT; LATANOPROST; LATANOPROST PLUS TIMOLOL MALEATE; LEVOBUNOLOL; LOPIDINE; METIPRANOLOL; PHOSPHOLINE; PHYSOSTIGMINE; PILOCARPINE; PILOPINE HS; PILOSTAT; RESULA; TIMOLOL; TIMOLOL MALEATE; TIMOPTIC XC; TRAVATAN Z; TRAVOPROST; UNCLASSIFIED DRUG;

CLINICAL STUDY; DRUG EFFICACY; DRUG STABILITY; EXPERIMENTAL STUDY; GLAUCOMA; INTRAOCULAR PRESSURE; MICROBIAL GROWTH; OPHTHALMOLOGY; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; CORNEA; CORNEAL DISEASES; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; PRESERVATIVES, PHARMACEUTICAL; VEHICLES;

EID: 33847013002     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328089f1c8     Document Type: Review

References (44)

1. Doǧan A, Orhan M, Söylemezoǧlu F, et al. Effects of antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Exp Ophthalmol 2004; 32:62-66.
2. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 2000; 22:167-208.
3. Scholz M, Lin JC, Lee VHL, Keipert S. Pilocarpine permeability across ocular tissues and cell cultures: influence of formulation parameters. J Ocul Pharmacol Ther 2002; 18:455-468.
4. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86:418-423.
5. Champeau EJ, Edelhauser HF. Effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. In: Holly F, Lamberts D, Mac Keen D, editors. The preocular tear film in health, disease, and contact lens wear. Lubbock, TX; 1998. pp. 292-302.
6. Eleftheriadis H, Cheong M, Sandeman S, et al. Corneal toxicity secondary to inadvertent use of benzalkonium chloride preserved viscoelastic material in cataract surgery. Br J Ophthalmol 2002; 86:299-305.
7. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol 2004; 32:180-184.
8. Debbasch C, Brignole F, Pisella PJ, et al. Quaternary ammonium and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001; 42:642-652.
9. De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjuctival cells. Curr Eye Res 2000; 20:85-94.
10. Katz LJ. Twelve-month evaluation of brimonidine-purite versus versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002; 11:119-126.
11. Baudouin C. Mechanism of failure in glaucoma filtrating surgery: A consequence of antiglaucomatous drugs? Int J Clin Pharmacol Res 1996; XVI (1):29-41.
12. Imayasu M, Moriyama T, Ichijima H, et al. The effects of daily wear of rigid gas permeable contact lenses treated with contact lens care solutions containing preservatives on the rabbit cornea. CLAO J 1994; 20:183-188.
13. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18:205-215.
14. http://www.emea.eu.int/htms/human/epar/epar.htm
15. Novack GD, Evans R. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization. J Glaucoma 2001; 10:483-486.
16. Easty DL, Nemeth-wasmer G, Vounatsos JP, et al. Comparison of nonpreserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol 2006; 90:574-578.
17. Lewis RA, Katz G, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007; 16:98-103. A clinical study that shows the efficacy and safety of travoprost with an alternative preservative system compared with travoprost preserved with 0.015% BAK.
18. Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998; 82:39-42.
19. Whitson JT,Ochsner KI, Moster MR, et al. The safety and intraocular pressurelowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology 2006; 113:1333-1339.
20. Gould HL. Solving the preservative paradox. Ophthalmology Manage 2006; August:47-52.
21. Liu Y, Yanai R, Lu Y, et al. Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fibroblasts. J Glaucoma 2006; 15:255-259.
22. Kovoor TA, Kim AS, McCulley JP, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens 2004; 30:90-94.
23. Ubels JL, McCartney MD, Lantz WK, et al. Effects of preservative-free artificial tear solutions on corneal epithelial structure and function. Arch Ophthalmol 1995; 113:371-378.
24. Ichijima H, Petroll WM, Jester JV, Cavanagh HD. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 1992; 11:221-225.
25. Hong S, Lee CS, Seo KY, et al. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol 2006; 142:185-186.
26. Guenoun JM, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctivederived epithelial cells. Invest Ophthalmol Vis Sci 2005; 46:2444-2450.
27. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004; 45:1360-1368.
28. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication: the conjunctival cell profile. Arch Ophthalmol 1994; 112:1437-1445.
29. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003; 12:486-490.
30. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 2005; 5:459-463.
31. Samples J, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp Eye Res 1989; 49:1-12.
32. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996; 7:80-86.
33. Broadway DC, Grierson I, O'Brian C, Hitchings RA. Adverse effects of topical antiglaucoma medications. II The outcome of filtration surgery. Arch Ophthalmol 1994; 112:1446-1454.
34. Johnson DH, Yoshikawa K, Brubaker RF, Hodge DO. The effect of long-term medical therapy on the outcome of filtration surgery. Am J Ophthalmol 1994; 117:139-148.
35. De Jong C, Solwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol 1994; 232:221-224.
36. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999; 106:556-563.
37. Baudouin C, Hamard P, Liang H, et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004; 111:2186-2192.
38. Kuppens EV, de Jong CA, Stiwijk TR, et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol 1995; 79:339-342.
39. Onofrey B, Fingeret M, Melton R, Semes L, Thomas R. Managing glaucoma and concomitant ocular surface disease. Rev Optom 2006.
40. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004; 23:490-496.
41. Su CY, Yang YC, Peng CF, et al. Risk of microbial contamination of unit-dose eyedrops within twenty four hours after first opening. J Formos Med Assoc 2005; 104:968-971.
42. Labbé A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzlkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 2006; 22:267-278. A study of two of the most prevalent preservatives used in ophthalmics solutions.
43. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human corneal epithelial cell culture system. Adv Ther 2006; 23:511-518. In this in-vitro study comparing the relative toxicity of the new formulation of travoprost 0.004% without BAC (travatan Z) with that of latonoprost 0.005% (0.02% BAC) on the immortalized HCEs, travatan Z was significantly less toxic than latonoprost (P<0.05). This might be of great value for patients who use topical glaucoma medications on a long-term basis.
44. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure of ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006; 23:1-9. A prospective in-vivo study conducted on the corneas of rabbits treated with either BAC-free travoprost 0.004% or latanoprost 0.005% (0.02%BAC) using confocal microscopy. Treatment with latanoprost caused pathological changes in the cornea while corneas treated with BAC-free travoprost were unaffected with no significant changes in epithelial cells, suggesting that this alternative preservative may offer patients with glaucoma a reduction in adverse events.